Kalbe Farma Tbk PT banner

Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 095 IDR -0.9% Market Closed
Market Cap: Rp51.3T

Gross Margin

39.5%
Current
Improving
by 1.2%
vs 3-y average of 38.3%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
39.5%
=
Gross Profit
Rp13.6T
/
Revenue
Rp34.4T

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
39.5%
=
Gross Profit
Rp13.6T
/
Revenue
Rp34.4T

Peer Comparison

Country Company Market Cap Gross
Margin
ID
Kalbe Farma Tbk PT
IDX:KLBF
49.6T IDR
Loading...
US
Eli Lilly and Co
NYSE:LLY
990.8B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
590.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
286.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
232.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
236.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
298.8B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
157.2B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD
Loading...

Market Distribution

Higher than 73% of companies in Indonesia
Percentile
73nd
Based on 1 215 companies
73nd percentile
39.5%
Low
-87 446.9% — 9.8%
Typical Range
9.8% — 37%
High
37% — 1 023 491.4%
Distribution Statistics
Indonesia
Min -87 446.9%
30th Percentile 9.8%
Median 20.5%
70th Percentile 37%
Max 1 023 491.4%

Kalbe Farma Tbk PT
Glance View

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 377.32 IDR
Undervaluation 20%
Intrinsic Value
Price
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
39.5%
=
Gross Profit
Rp13.6T
/
Revenue
Rp34.4T
What is Kalbe Farma Tbk PT's current Gross Margin?

The current Gross Margin for Kalbe Farma Tbk PT is 39.5%, which is above its 3-year median of 38.3%.

How has Gross Margin changed over time?

Over the last 3 years, Kalbe Farma Tbk PT’s Gross Margin has decreased from 40.7% to 39.5%. During this period, it reached a low of 37.2% on Jun 30, 2024 and a high of 40.7% on Sep 30, 2022.

Back to Top